160 related articles for article (PubMed ID: 19093203)
1. Serum alpha-fetoprotein levels during and after interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C.
Tamura Y; Yamagiwa S; Aoki Y; Kurita S; Suda T; Ohkoshi S; Nomoto M; Aoyagi Y;
Dig Dis Sci; 2009 Nov; 54(11):2530-7. PubMed ID: 19093203
[TBL] [Abstract][Full Text] [Related]
2. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
3. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.
Asahina Y; Tsuchiya K; Nishimura T; Muraoka M; Suzuki Y; Tamaki N; Yasui Y; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Nakagawa M; Kakinuma S; Watanabe M; Izumi N
Hepatology; 2013 Oct; 58(4):1253-62. PubMed ID: 23564522
[TBL] [Abstract][Full Text] [Related]
4. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus.
Tateyama M; Yatsuhashi H; Taura N; Motoyoshi Y; Nagaoka S; Yanagi K; Abiru S; Yano K; Komori A; Migita K; Nakamura M; Nagahama H; Sasaki Y; Miyakawa Y; Ishibashi H
J Gastroenterol; 2011 Jan; 46(1):92-100. PubMed ID: 20711614
[TBL] [Abstract][Full Text] [Related]
5. The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C.
Dohmen K; Kawano A; Takahashi K; Shigematsu H; Tanaka H; Haruno M; Yanagita K; Ichiki Y; Mori T; Hayashida K; Shimoda S; Ishibashi H; Nomura H
Hepatogastroenterology; 2013; 60(128):2034-8. PubMed ID: 24719946
[TBL] [Abstract][Full Text] [Related]
6. Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study.
Osaki Y; Ueda Y; Marusawa H; Nakajima J; Kimura T; Kita R; Nishikawa H; Saito S; Henmi S; Sakamoto A; Eso Y; Chiba T
J Gastroenterol; 2012 Apr; 47(4):444-51. PubMed ID: 22105231
[TBL] [Abstract][Full Text] [Related]
7. Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: Prioritize who needs urgent direct-acting antiviral agents.
Huang CM; Hu TH; Chang KC; Tseng PL; Lu SN; Chen CH; Wang JH; Lee CM; Tsai MC; Lin MT; Yen YH; Hung CH; Cho CL; Wu CK
Medicine (Baltimore); 2017 Nov; 96(46):e8696. PubMed ID: 29145306
[TBL] [Abstract][Full Text] [Related]
8. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.
Oze T; Hiramatsu N; Yakushijin T; Miyazaki M; Yamada A; Oshita M; Hagiwara H; Mita E; Ito T; Fukui H; Inui Y; Hijioka T; Inada M; Katayama K; Tamura S; Yoshihara H; Inoue A; Imai Y; Hayashi E; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hamasaki T; Hayashi N; Takehara T;
Clin Gastroenterol Hepatol; 2014 Jul; 12(7):1186-95. PubMed ID: 24321207
[TBL] [Abstract][Full Text] [Related]
9. Direct acting antiviral-induced dynamic reduction of serum α fetoprotein in hepatitis C patients without hepatocellular carcinoma.
Huynh T; Hu KQ
Front Med; 2019 Dec; 13(6):658-666. PubMed ID: 31655955
[TBL] [Abstract][Full Text] [Related]
10. Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis.
Masetti C; Lionetti R; Lupo M; Siciliano M; Giannelli V; Ponziani FR; Teti E; Dell'Unto C; Francioso S; Brega A; Montalbano M; Visco-Comandini U; Taibi C; Galati G; Vespasiani Gentilucci U; Picardi A; Andreoni M; Pompili M; Pellicelli AM; D'Offizi G; Gasbarrini A; De Santis A; Angelico M
J Viral Hepat; 2018 Dec; 25(12):1493-1500. PubMed ID: 30112854
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-17 haplotyping predicts hepatocellular carcinoma in sofosbuvir, pegylated interferon-alpha-2a & ribavirin treated chronic hepatitis C patients.
Mostafa AM; Saafan HA; Al-Tawashi AS; Kasem MH; Alaa AM; Eltobgy MM; Moubarak AS; Gharib MM; Awwad MA; Omar HM; El-Derany MO
Virus Res; 2021 Jan; 292():198226. PubMed ID: 33171166
[TBL] [Abstract][Full Text] [Related]
12. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974
[TBL] [Abstract][Full Text] [Related]
13. Lysyl oxidase-like 2 as a predictor of hepatocellular carcinoma in patients with hepatitis C virus after sustained virological response.
Chida T; Ohta K; Noritake H; Matsushita M; Murohisa G; Kageyama F; Sasada Y; Oyaizu T; Tsugiki M; Tamakoshi K; Nakajima T; Suda T; Kawata K
Sci Rep; 2024 May; 14(1):10864. PubMed ID: 38740815
[TBL] [Abstract][Full Text] [Related]
14. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.
Nagata H; Nakagawa M; Asahina Y; Sato A; Asano Y; Tsunoda T; Miyoshi M; Kaneko S; Otani S; Kawai-Kitahata F; Murakawa M; Nitta S; Itsui Y; Azuma S; Kakinuma S; Nouchi T; Sakai H; Tomita M; Watanabe M;
J Hepatol; 2017 Nov; 67(5):933-939. PubMed ID: 28627363
[TBL] [Abstract][Full Text] [Related]
15. Marked reduction of the alpha-fetoprotein levels among individuals with chronic hepatitis C, following PEG-interferon and ribavirin treatment.
Aladag M; Camci C; Huang Y; Wright H; Rizvi S; Gurakar A; Stokes K; Sebastian A
J Clin Gastroenterol; 2005; 39(10):923-4. PubMed ID: 16208125
[No Abstract] [Full Text] [Related]
16. High Post-treatment α-Fetoprotein Levels and Aspartate Aminotransferase-to-Platelet Ratio Index Predict Hepatocellular Carcinoma in Hepatitis C Virus Decompensated Cirrhotic Patients with Sustained Virological Response After Antiviral Therapy.
Ji F; Zhou R; Wang W; Bai D; He C; Cai Z; Shen Y; Wang S; Deng H; Li Z
J Interferon Cytokine Res; 2017 Aug; 37(8):362-368. PubMed ID: 28731786
[TBL] [Abstract][Full Text] [Related]
17. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
J Med Virol; 2007 Oct; 79(10):1485-90. PubMed ID: 17705189
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
[TBL] [Abstract][Full Text] [Related]
19. Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients.
Cedrone A; Covino M; Caturelli E; Pompili M; Lorenzelli G; Villani MR; Valle D; Sperandeo M; Rapaccini GL; Gasbarrini G
Hepatogastroenterology; 2000; 47(36):1654-8. PubMed ID: 11149026
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Sofosbuvir Plus Ribavirin Treatment with Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2.
Seo K; Kim SK; Kim SR; Ohtani A; Kobayashi M; Kato A; Morimoto E; Saijo Y; Kim KI; Imoto S; Kim CW; Yano Y; Kudo M; Hayashi Y
Dig Dis; 2017; 35(6):541-547. PubMed ID: 29040986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
